Antimalarial Inhibitors that Target the Plasmodial Surface Anion Channel (PSAC) Protein and Development of the PSAC Protein as Vaccine Targets
There are two related technologies, the first being small molecule inhibitors of the malarial plasmodial surface anion channel (PSAC) and the second being the PSAC protein itself as a vaccine candidate. The PSAC protein is produced by the malaria parasite within host erythrocytes and is crucial for mediating nutrient uptake. In vitro data show that the PSAC inhibitors are able to inhibit growth of malaria parasites, have high specificity, and low toxicity. Portions of the PSAC protein are found on the outer surface of infected host erythrocytes and the protein was recently shown to be encoded by the clag3 gene. This discovery opens the possibility of developing the PSAC protein as a potential vaccine candidate against malaria.
|Potential Commercial Applications:||Competitive Advantages:||
Sanjay Desai (NIAID)
US Application No. 61/474,583
PCT Application No. PCT/US12/33072
Pillai AD, et al. PMID 22949525
Desai SA. PMID 22432505
Nguitragool W, et al. PMID 21620134
Pillai AD, et al. PMID 20101003
The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize Antimalarial Inhibitors that Target the Plasmodial Surface Anion Channel (PSAC) Protein. For collaboration opportunities, please contact Dana Hsu at firstname.lastname@example.org or 301-451-3521.
Kevin Chang , Ph.D.
NIH Office of Technology Transfer
OTT Reference No: E-145-2011/0